目的 探究吡格列酮联合二甲双胍对2型糖尿病伴血脂紊乱患者脂联素(APN)、视黄醛结合蛋白-4(RBP-4)水平和胰岛素抵抗的影响.方法 回顾性分析2014年1月~2015年1月本部收治的68例2型糖尿病伴血脂紊乱患者的临床资料,根据治疗方法的不同,分为研究组和对照组各34例,对照组患者接受二甲双胍治疗,研究组则在对照组的基础上接受吡格列酮治疗.比较两组患者治疗前和治疗后体质量指数(BMI)、APN、RBP-4以及其他糖脂代谢指标的变化.结果 治疗后,两组患者的三酰甘油(TG)、总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)水平明显降低,而高密度脂蛋白胆固醇(HDL-C)明显升高,与治疗前比较,差异有统计学意义(P<0.05);研究组TG、TC和LDL-C水平显著低于对照组,而HDL-C和则显著高于对照组,差异有统计学意义(P<0.05).结论 吡格列酮联合二甲双胍可以有效降低患者血糖水平,改善血脂紊乱,且能调节患者血清APN和RBP-4的水平,进一步改善患者胰岛素抵抗.%Objective To discuss the impact of APN, RBP-4 and insulin resistance on patients with type 2 diabetes and hyperlipidemia treated with pioglitazone and metformin. Methods Sixty-eight patients with type 2 diabetes and hyperlipidemia from January 2014 to January 2015 were retrospective analyzed. They were divided into two groups according to their treatment methods. The control group was made up of 34 patients treated with metformin while the research group was made up of the other 34 patients, who were treated with metformin and pioglitazone. The patients were observed and BMI, APN, RBP-4, and indexes related to blood glucose and other treatments were compared between the two groups. Results The TG, TC and LDL-C levels decreased and the HDL-C level increased in the two groups following the treatments;the differences between two groups were statistically significant (P<0.05). The TG, TC and LDL-C levels in the research group following the treatment were all lower than those of the control group, but the HDL-C level in the research group was higher than that in control group. The differences between the two groups were statistically significant (P<0.05). Conclusion The combination of pioglitazone and metformin in the treatment of patients with type 2 diabetes and dyslipidemia can reduce blood glucose levels, improve blood lipids and effectively adjust patients' levels of APN and RBP-4, which suggests that it may be useful for improving insulin resistance.
展开▼
